LQDA News & Analysis
3 articles
Market Mood
Liquidia (LQDA) Stock Price Target Cut to $58 on Patent Uncertainty
H.C. Wainwright has reduced its price target for Liquidia (LQDA) to $58 due to ongoing patent uncertainty. This adjustment highlights potential challenges for the company's market position and future revenue. The revised target suggests concerns regarding the sustainability of its current business operations, which could impact investor confidence. Investors need to be aware of the implications of patent-related issues, as they may influence Liquidia's financial stability and growth prospects.
Read More: Liquidia (LQDA) Stock Price Target Cut to $58 on Patent Uncertainty
Liquidia (LQDA) Achieves 178.79% Share Gain Over Past Year
Greenhaven Road Capital reported a net return of approximately 11% for Q2 2026. It highlighted Liquidia Corporation (NASDAQ: LQDA), which has a market capitalization of $6.66 billion, closed at $74.44 per share on August 14, 2026. Liquidia's shares gained 178.79% in the past 52 weeks, and it has a one-month return of 0.26%. Greenhaven realized a short-term gain on LQDA shares, which appreciated over 30% prior to a patent dispute verdict, indicating potential for future investment revisitation. This matters for investors as it showcases significant momentum in LQDA’s stock performance amidst market challenges.
Read More: Liquidia (LQDA) Achieves 178.79% Share Gain Over Past Year
Liquidia CCO Sells 80,000 Shares for $2.8 Million
The Chief Commercial Officer of Liquidia Corporation (LQDA) sold 80,000 shares, totaling approximately $2.8 million. This transaction may raise concerns among investors regarding insider sentiment. The sale was executed at an average price of $35 per share. This event comes amid ongoing developments in the biotech sector, influencing LQDA's stock performance.
Read More: Liquidia CCO Sells 80,000 Shares for $2.8 Million